Zeo ScientifiX, Inc 8-K, filed Nov 15, 2024
Zeo ScientifiX, Inc. (ZEOX)
About this 8-K
Zeo ScientifiX, Inc filed this 8-K on November 15, 2024.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.
| Item 7.01 | Regulation FD Disclosure. |
On November 15, 2024, Robin L. Smith, M.D., M.B.A., a co-founder of Exotropin, LLC (“Exotropin”), will be conducting a presentation entitled “Exosomes are the new Frontier in Aesthetics: Not All Exosomes are Alike” at the Medical Aesthetics Professionals (“MAP”) meeting being held in Scottsdale, Arizona., Exotropin is a privately-held developer of advanced cosmeceuticals using exosomes and other proprietary technology. ZEO holds a minority equity interest in Exotropin and is collaborating with Exotropin on the development of various products, including, ZEO HAIR GROW™ Powered By Exotropin™, which is being introduced at the MAP meeting and which is featured in the presentation.
A copy of the PowerPoint slides pertaining to the ZEO HAIR GROW™ Powered By Exotropin™ to be used in connection with Dr. Smith’s presentation is attached as Exhibit 99.1 to this Report.
The foregoing information, including the PowerPoint presentation attached as Exhibit 99.1 to this Report, is being furnished pursuant to Item 7.01 of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1* | November 15, 2024 PowerPoint Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Furnished but not filed. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 15, 2024 | ZEO SCIENTIFIX, INC. | |
| By: | /s/ Ian T. Bothwell | |
| Ian T. Bothwell | ||
| Interim Chief Executive Officer and Chief Financial Officer | ||
2
Exhibit 99.1
P r i v a te a n d Co nfide n tial. © 2 024 Z EO S c i e n tifi X , I n c . All r i gh t s r eserv ed.
• G loba l busines s lead e r , medi c a l d o c t o r , a u tho r , spe a k er a n d ent r e p r eneur in th e hea lth c a re indu s t r y . • T r ailb l a z er in r e g ene r a ti v e medi c ine a n d p r e d i c t i v e a n al y ti c s a n d h a s f ocused on tu r n a r o u nd s , M& A a n d disrupti v e inn o v a tion s in m e d i c in e . • R e c ei v ed B . A . f r om Y al e Uni v e r sit y , M. D . f r om th e Y ale Sch o ol of Med i c i n e , M. B . A . f r om th e W h a r t on Sch o ol of Busines s , th e S t a n f o r d Uni v e r sity Di r e c t o r s P r og r a m a n d r e c ei v ed a n hon o r a r y Do c t or of Scien c e d e g r ee f r om T JM C . • F o u nde d Spirit u s The r apeutic s , E x ot r o p i n , L L C a nd Neo s t em , th e Cu r a F o u nd a tio n a n d BRM H o ld i ng s . • S e r v ed a s a memb er of th e e x e c uti v e bo a r d of tr u s t ees of S a n f o r d He a lth, S a n f o r d He a lth ’ s In t er n a tion al Bo a r d a n d th e b o a r d of tr u s t ees of th e New Y o r k Uni v e r sity L a n g o n e Medic a l Cen t er a s w ell a s ch a ir m a n of th e b o a r d of di r e c t o r s of th e New Y o r k Uni v e r sity H o spi t a l f or Join t D isease s . R o b in L. Smith , M. D ., M B A
E x os om e s pr o v id e signal to: • R epa i r • R estore • R eju v ena te • R eplenish NEW F R O N T I ER IN B E A UTY A N D AN T I - A G I NG E x oso m e s c a rry p r otein s , peptide s , lipi d s and nu c lei c acids that pl a y a vital r ole i n ren e wing and reju v ena ti ng t h e appea ra nce of skin and hai r . When appli ed to p ic a ll y , t h r oug h intercel lu lar c o mm u n i c a t i o n , e x osomes deli v er their cargo to assist with a v ast ar r a y of fu n c t io ns to en h ance t h e o v e r all condition of t h e scalp and hai r . • R educe en v i r onme n t al stress • R eden sify • R en e w • R e g ene r a te
TH E G R O WIN G H A IR L OS S I N DU S T R Y $3 .5 B i l l i o n s p ent on al l h a ir los s treatm e nts “ 99 % of a l l p r oducts Bein g ma r k et in g are completely inef f ecti v e” W ashi n gt o n P ost H air R es t o r a t i on P a tie n ts 358 , 1 0 9 s u r g ic a l pa tients 697 , 3 7 2 no n - s u r g ic a l pa tients $2 .5 B i lli o n s p ent on s u r g ic a l p r ocedu r es H o w ma n y pe o pl e i n the U . S . a r e e x p er i en cin g h a i r loss? 35 mil M en 3 1 mil W omen 202 0 P r a c tic e Cen s u s Res u l t s – I n t er n a ti o n al Socie t y of Hair Res t o r a ti o n Su r g ery
HAIR L O S S IS M U L T I F A C T ORIAL R et u r n A n a gen Phas e s of Hair G r owth C a t a gen T e l ogen An a gen TH E APP R O A C H T O R E V I T ALIZE TH E C ON D I T ION A N D APPP E AR A N C E O F H AIR MU S T BE AS W E LL
A 9 0 - D A Y PH Y S I CIA N F ORMUL A TE D HAIR G R O W S Y S TEM A U N IQUE FIR S T - O F - IT S - KI N D S Y STEM A Multi f act o r i al Approa c h C o m bi n i n g the Syn e r gistic & Com p liment a r y P o wer of • Amniotic Fluid Ext r act E x osomes (G R O WX) • Adipose Deri v ed E x os o m es (eX o 3 ) • Aloe V e r a E x os o mes (alo e 3 ) T o R eplenish and Opti m i z e the C o n dit i on of the Scalp and Promote the Appea r ance of Thic ke r , Fuller Lo o king H a ir
TH E P O TEN T C OM B IN A T I O N BE H IND TH E Z E O HAIR G R O W S Y S TEM aloe 3 (Aloe) E x osomes e X o 3 (ASC) E x osomes ZEO HA I R GR O W in c lu d es t h e po t e n t c om b i n a ti o n of th r ee d if f e r e n t sou r ce s of e x osomes and ad d ed sig n ali ng molec u le s f o rm ul a ted to g et h er in t o a system designed to ren e w and reple n is h, maki n g y our hai r loo k ful le r , st r on g er and t h i c k e r . Each e x os ome so u rc e has its o wn u n ique sign a tu r e , crea ti ng an unma t c hed solut io n f or restorin g t h e vit a li t y of t h e scalp and imp r oving t h e hair ’ s cond i tion and ap p ea ra nc e . Amniotic Fl u id ( AF) or P P X A u t ol o g o u s E x osomes
C OMPL E MEN T A R Y & S YNE R G I S T I C S E CRE T OM E S Z E O G RO W X + Z E O G RO W BO O S T A m niotic Fluid Ext r act + P ot e nt G r o w th F acto r Booster I n O f f i c e “ I nduct i on / Sti m ulat i on” P r ocedu r e E X O F OLL I CL E FUEL e X o 3 E x os o m es + al oe 3 E x os o m es Hair & S ca l p S p r a y At Ho m e M ainte nance P r ot o co l De l i v ers n e ce s s ar y s u ppo r t f or scalp h e alth until n e xt G R O WX + G R O W B OO ST In O f f i c e p r o cedu re Th e Se qu e n tial Comb i n e d A p p r oach • F o r m ul at ed to s u p p o r t a n d m a i n t a i n t he env i r onment of t he sca l p t o p r omote h ea lt h y h a i r , a n d na t u r al g r o wth. • P r ovi d es es s en t ia l nu t rie nt s t o comp l e t ely nou r is h a n d h y d r a t e t he sca l p a n d h a i r . • T a r g e t ed f o r m ul at ion s t o p r o t ect t he sca l p a n d re d uce f a cto r s cau s in g env i r onmen t al a n d me c h a nic a l st r e s s o r s t o t he scalp a nd h a ir f ollicles i n or d er t o t hi c k en a n d re d en s if y h a i r . • D elive r in g t h e ne c e ssar y a n d r elev a n t f o rt i f yin g r e s ou r c e s t o r e p leni s h , str en gt he n a n d o pt i m iz e t h e c on d i t io n a n d app e ara n c e o f t h e h a i r a n d s c a l p .
W E INVITE Y OU T O VISI T US A T BO O T H #609